Action Vaxcyte - PCVX

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

73,02

Prix Achat

69,00

Prix Vente

80,70

Volume échangé

0,00 Fourchette du Jour 0,00

58,10 Plage de 52 semaines 121,055

Cap du marché

9,101B

Clôture Veille

73,02

Ouverture

Dernière Transaction

72.56

Dernière heure de transaction

11:22:00

Volume financier

VWAP

Volume moyen (3 m)

1 126 728

Actions en circulation

124 636 546

Rendement du Dividende

Ratio Cours sur Bénéfices

-22,62

Bénéfice par action (BPA)

-3,23

Chiffre d'affairess

Bénéfice net

-402,27M

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine.

Secteur

Biological Pds,ex Diagnstics

Industrie

Biological Pds,ex Diagnstics

Site Web

www.vaxcyte.com

Siège social

Wilmington, Delaware, USA

Fondé

Vaxcyte Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker PCVX. Le dernier cours de clôture d'Vaxcyte était de US$73,02. Au cours de la dernière année, les actions de Vaxcyte ont été négociées dans une fourchette de prix de US$ 58,10 à US$ 121,055.

Vaxcyte compte actuellement 124 636 546 actions en circulation. La capitalisation boursière d'Vaxcyte est de US$9,10 milliard. Vaxcyte a un ratio cours/bénéfice (ratio PE) de -22.62.

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3...

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-6.76	-8.47330157934	79.78	83.33	70.11	1632465	76.53381835	CS
4	-15.18	-17.2108843537	88.2	91.77	70.11	1077688	81.61042884	CS
12	-20.66	-22.0538001708	93.68	94.5999	70.11	1126728	84.99709529	CS
26	-34.65	-32.1816662023	107.67	121.055	70.11	1210733	96.29635132	CS
52	1.17	1.62839248434	71.85	121.055	58.1	933673	87.64383329	CS
156	48.21	194.316807739	24.81	121.055	17.44	780382	61.68709062	CS
260	49.46	209.932088285	23.56	121.055	15.51	585365	56.24186466	CS

PCVX - Frequently Asked Questions (FAQ)

What is the current Vaxcyte share price?

The current share price of Vaxcyte is US$ 73,02

How many Vaxcyte shares are in issue?

Vaxcyte has 124 636 546 shares in issue

What is the market cap of Vaxcyte?

The market capitalisation of Vaxcyte is USD 9,1B

What is the 1 year trading range for Vaxcyte share price?

Vaxcyte has traded in the range of US$ 58,10 to US$ 121,055 during the past year

What is the PE ratio of Vaxcyte?

The price to earnings ratio of Vaxcyte is -22,62

What is the reporting currency for Vaxcyte?

Vaxcyte reports financial results in USD

What is the latest annual profit for Vaxcyte?

The latest annual profit of Vaxcyte is USD -402,27M

What is the registered address of Vaxcyte?

The registered address for Vaxcyte is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

What is the Vaxcyte website address?

The website address for Vaxcyte is www.vaxcyte.com

Which industry sector does Vaxcyte operate in?

Vaxcyte operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
BTOGBit Origin Ltd	US$ 0,9285 (410,16%)	58,85M
ACONAclarion Inc	US$ 6,50 (94,03%)	11,5M
FTFTFuture FinTech Group Inc	US$ 0,3205 (58,66%)	26,52M
BSCUInvesco BulletShares 2030 Corporate Bond ETF	US$ 24,99 (50,45%)	3
LGHLWLion Group Holding Ltd	US$ 0,0093 (38,81%)	10
LXRXLexicon Pharmaceuticals Inc	US$ 0,32 (-54,25%)	4,66M
BSCSInvesco Bulletshares 2028 Corporate Bond ETF	US$ 10,01 (-50,79%)	1
TOIIWOncology Institute Inc	US$ 0,02 (-45,80%)	1
AGMHAGM Group Holdings Inc	US$ 0,198 (-39,74%)	389,35k
CTKBCytek Biosciences Inc	US$ 2,71 (-39,64%)	3
BTOGBit Origin Ltd	US$ 0,9285 (410,16%)	58,85M
FTFTFuture FinTech Group Inc	US$ 0,3205 (58,66%)	26,52M
ARBKArgo Blockchain PLC	US$ 0,438 (7,51%)	17,11M
ACONAclarion Inc	US$ 6,50 (94,03%)	11,5M
ADTXAditxt Inc	US$ 0,0629 (1,94%)	11,45M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Vaxcyte Inc (PCVX)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Vaxcyte Inc

PCVX Dernières nouvelles

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

PCVX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Vaxcyte Inc (PCVX) Cours

Vaxcyte Inc (PCVX)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Vaxcyte Inc

PCVX Dernières nouvelles

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

PCVX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités